Research ArticleCancer
High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides
- Adele de Masson1,*,
- John T. O’Malley1,*,
- Christopher P. Elco1,
- Sarah S. Garcia1,
- Sherrie J. Divito1,
- Elizabeth L. Lowry1,
- Marianne Tawa1,
- David C. Fisher2,
- Phillip M. Devlin3,
- Jessica E. Teague1,
- Nicole R. Leboeuf1,
- Ilan R. Kirsch4,
- Harlan Robins4,
- Rachael A. Clark1,†,‡ and
- Thomas S. Kupper1,†,‡
- 1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
- 2Center for Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
- 3Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
- 4Adaptive Biotechnologies, Seattle, WA 98102, USA.
- ↵‡Corresponding author. Email: tkupper{at}bwh.harvard.edu (T.S.K.); rclark{at}bwh.harvard.edu (R.A.C.)
See allHide authors and affiliations
Science Translational Medicine 09 May 2018:
Vol. 10, Issue 440, eaar5894
DOI: 10.1126/scitranslmed.aar5894
Vol. 10, Issue 440, eaar5894
DOI: 10.1126/scitranslmed.aar5894
Adele de Masson
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
John T. O’Malley
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Christopher P. Elco
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Sarah S. Garcia
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Sherrie J. Divito
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Elizabeth L. Lowry
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Marianne Tawa
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
David C. Fisher
Center for Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Phillip M. Devlin
Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Jessica E. Teague
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Nicole R. Leboeuf
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Ilan R. Kirsch
Adaptive Biotechnologies, Seattle, WA 98102, USA.
Harlan Robins
Adaptive Biotechnologies, Seattle, WA 98102, USA.
Rachael A. Clark
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Thomas S. Kupper
Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
